Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Premier Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$7,420,427

1,381 payments

Through program year 2025, Premier Clinical Research is reported as receiving $7,420,427 in research payments, across 1,381 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $410,160 80
2024 Research $811,550 156
2023 Research $1,402,433 150
2022 Research $950,508 346
2021 Research $1,118,996 183
2020 Research $1,430,464 204
2019 Research $1,296,318 262

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $2,219,942 398 payments
  2. Ucb SA $1,437,378 27 payments
  3. Eli Lilly and Company $500,088 27 payments
  4. Avanir Pharmaceuticals, Inc. $463,743 102 payments
  5. GlaxoSmithKline, LLC. $456,520 260 payments
  6. H. Lundbeck A S $397,730 51 payments
  7. E.R. Squibb & Sons, L.L.C. $324,230 14 payments
  8. Aclaris Therapeutics, Inc. $221,180 24 payments
  9. Bausch Health US, LLC $205,165 28 payments
  10. Novartis Pharmaceuticals Corporation $202,793 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $761,556 13 payments
  2. A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines $727,379 24 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Pso $314,498 2 payments
  4. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $239,190 41 payments
  5. A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) $236,760 38 payments
  6. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $221,180 24 payments
  7. A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines $199,748 13 payments
  8. A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis $184,598 4 payments
  9. A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines $184,263 15 payments
  10. Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis $172,456 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record